The field built chips for organs. Nobody built one for peptides and stem cells.
Organ-on-a-chip technology lets researchers test medicines on living human tissue instead of animals — and since 2022, US law no longer forces the animal detour. But every commercial platform answers the same general question. PepStemChip, invented by Bogdan Dicoias at Panacea Bio Chem, is the organ-chip designed around the two classes of medicine that never got their own testbed: peptides and stem cells.
What an organ-on-a-chip is
Take a transparent slab the size of a USB stick, etch hair-width channels into it, and line those channels with living human cells. Push fluid through like blood, stretch it like breathing tissue, keep two cell types talking across a membrane. What you get is not a model of an organ on a computer — it is a working piece of organ-level biology you can hold in your hand.
An organ's job, miniaturised
The landmark 2010 lung-on-a-chip from Donald Ingber's group at Harvard's Wyss Institute reproduced the alveolar–capillary interface — air on one side, blood-like flow on the other, and the mechanical rhythm of breathing itself. Cells behaved like lung because the chip made them live like lung.
Why mechanics matter
Cells in a flat plastic dish experience no flow, no stretch, no gradients — an existence no real tissue knows. Chips restore the physical cues, and with them, tissue-level behaviour: barrier function, immune responses, realistic drug metabolism.
A human testbed, not a mouse
Chips carry human cells, so results are not filtered through a rodent's metabolism. That matters most exactly where drugs fail: species-specific toxicity and efficacy that animal studies miss.
Now written into law
The FDA Modernization Act 2.0 (December 2022) ended the blanket mandate for animal testing before human trials, opening the door for organ-chip data in drug applications. In April 2025 the FDA published a roadmap to reduce animal testing — naming organ-chips among the replacement methods.
Why the old pipeline keeps failing
Roughly nine out of ten drug candidates that enter human trials after passing animal studies never reach patients. The chip field exists because of that number.
The animal detour
- Mandated since 1938: test in animals first, then humans. Mice are not small humans — receptors, metabolism and immunity diverge at exactly the points drugs act.
- Analyses put clinical attrition around 90%, dominated by failures of efficacy and toxicity that animal studies did not predict.
- Decades of effort and billions in funding are spent learning, late, that a mouse result did not transfer.
The chip answer — and its blind spot
- Commercial platforms — Emulate (spun out of the Wyss Institute in 2014) and CN Bio (an Oxford spin-out) among the leaders — sell organ mimics for general drug screening: liver for toxicity, gut for absorption, multi-organ links for whole-body questions.
- The blind spot: these are general-purpose organs answering general questions. Peptides — fragile, fast-degrading, receptor-precise molecules — and stem cells — living medicines that expand, drift and differentiate — have no dedicated testbed.
The gap nobody filled
Peptides are the fastest-growing class in modern drug discovery, and stem-cell therapies are medicine's longest-standing promise. Both are tested today on platforms designed for neither.
Peptides break the standard assay
A peptide can be degraded by enzymes in minutes, bind its receptor with nanometre precision, and behave differently under flow than in a static well. Generic organ-chips were engineered around small-molecule ADME questions, not around the life cycle of a peptide.
Stem cells are a moving target
A stem-cell culture is not a reagent — it expands, competes, drifts and differentiates. Testing what a peptide does to a stem-cell population requires a platform where the cells' environment is controlled hour by hour and observed continuously, not sampled destructively.
Two gaps, one origin
Peptide fate and stem-cell fate are decided in the same place: a living micro-environment with flow, mechanics and gradients. Whoever builds a chip for one has built most of a chip for the other.
An empty shelf
Survey the commercial organ-chip catalogues and you will find liver, lung, gut, kidney, brain and tumour models. We are not aware of any commercially available organ-chip platform designed specifically around peptide testing, or around the peptide–stem-cell interplay. That is the shelf PepStemChip occupies.
PepStemChip — Panacea's answer
Panacea Bio Chem works where peptides and living cells meet — amino-acid-chain design, formulation, lyophilization. PepStemChip is the organ-on-a-chip platform invented here by Bogdan Dicoias to close the gap above: a testbed engineered from the start around how peptides actually behave in living micro-environments, and around how stem cells respond to them over time — so a candidate chain meets realistic human biology before it ever meets an animal, let alone a person.
We are deliberately telling you the gap it fills, not the blueprint. The architecture, materials and operating parameters are Panacea intellectual property and will be disclosed with data, not adjectives — the same discipline our LyoLevit aerogel work follows. What we can say plainly: the platform exists, it is ours, and it is built for the two classes of medicine the chip revolution left standing at the door.
In-house platform · design disclosure follows peer review
"The chip pioneers taught cells to live like organs. Beautiful work — and entirely general. But a peptide does not need a generic organ; it needs the two minutes of flow, enzyme and receptor that decide whether it lives or dies. And a stem cell needs an address, not a dish. We built the testbed for the molecules and cells that everyone else asked to wait outside."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
What we show, and what we hold back
This page positions a platform, so it carries an honest boundary. Everything stated about the organ-on-a-chip field above is public record, credited on The Research page with names and years. Everything stated about PepStemChip is a statement of purpose and scope — the design itself remains Panacea intellectual property until peer-reviewed publication, and no performance figures are claimed here.
Shown
The field's credited history, the regulatory shift that made organ-chip data count, the specific gap — no peptide-specific, no stem-cell-specific commercial testbed — and the fact that Panacea has built a platform to fill it.
Held back
Channel architecture, membrane and materials choices, actuation method, sensing stack and operating parameters. The gap is the story today; the blueprint will be the story after peer review.
The gap-check ledger
A claim that a shelf is empty is only as good as the last time someone looked. So the claim at the centre of this page is kept as a dated ledger — each entry records what was searched, what was observed, and what would change our mind.
- 2026-09-05 — Commercial organ-chip vendor landscape queried. The observed set — Emulate, CN Bio, Mimetas, TissUse, Hesperos, Nortis — organises its catalogues by organ (liver, lung, gut, kidney, brain), not by molecule class. No vendor in the observed set highlighted peptide drug testing as a distinct platform focus.
What a ledger entry does not mean: absence in one dated search is not proof of universal absence — a specialised startup could exist unindexed, and vendors may run peptide projects as custom services without productising a platform. What closes the ledger: any vendor productising a peptide-specific organ-chip. The day that appears, this page says so.
Peptides and the FDA's NAMs shift
The regulatory door opened in two moves — one for drugs in general, one naming the methods. Neither was written with peptides in mind, which is precisely the opening.
2022 — the blanket mandate falls
The FDA Modernization Act 2.0 (S.5002, 117th Congress) removed the requirement that every drug be tested in animals before human trials, making data from new approach methodologies — organ-chips among them — admissible in support of applications. Admissible is not sufficient: the evidence still has to carry the application. S.5002 text (govinfo)
2025 — a roadmap, monoclonal-antibody first
In April 2025 the FDA announced a plan to phase out the animal-testing requirement for monoclonal antibodies and other drugs, explicitly naming organ-on-a-chip systems among the human-relevant methods, with a pilot program as the entry point. Peptides are not the named frontier of that roadmap; guidance written for peptide-specific NAMs does not yet exist. FDA press announcement, April 2025
Why that gap favours a peptide testbed
Regulatory writers generalise from the methods in front of them. The vendor layer builds general organ models, so the regulatory record is being written around general organ models. A platform designed around peptide fate — enzyme exposure, receptor binding, flow — is the kind of instrument the peptide chapter of NAMs will eventually need data from.
What this page does not claim
The FDA has not ended animal testing — the 2025 announcement is a plan with a defined first scope. Chip data does not yet replace animal data in general, and PepStemChip has submitted nothing to any regulator. The shift is real; its peptide chapter is unwritten.
Frequently asked questions
What is an organ-on-a-chip?
A microfluidic device lined with living human cells that reproduces key organ functions — flow, mechanical forces, tissue interfaces — so human biology can be studied without animals.
Why do animal models fail translation?
Species differ in metabolism, receptors and immunity. Around 90% of drug candidates entering human trials after animal studies never reach the market, mostly on efficacy or toxicity the animals did not show.
What did the FDA Modernization Act 2.0 change?
It removed the blanket pre-trial animal-testing mandate (December 2022), letting developers support applications with alternatives — including organ-chip data.
What makes PepStemChip different?
Commercial platforms model organs for general drug screening. PepStemChip is designed around peptides and stem cells — the two classes without a dedicated testbed. More on the Questions page.
Trending in the field
Recent developments in the field — refreshed 2026-11-02 by Panacea Bio Chem.
- Nanoparticle delivery systems for gene therapy of degenerative musculoskeletal diseases — PubMed, 2026 Nov
- Correction: From biological scaffold to multifunctional bioplatform: research progress and applications of decellularized extracellular matrix — PubMed, 2026
- Paving the way for translational relevance in advanced therapies in Brazil: conference report from SBINT 2025 — PubMed, 2026 Oct 30
- Modeling Early Metastatic Progression in Breast Cancer Using a Barrier-Free, Perfusable Spheroid-on-a-Chip Platform — PubMed, 2026 Oct 28
